

Press Release
07 February 2022 10:00:00 CET



Export order received

Newbury Pharmaceuticals AB's subsidiary in Switzerland received an international export order of private label pharmaceuticals with a total value of approx. 370 KUSD. Shipment of the order is planned in May.

The subsidiary in Switzerland conducts international sales of pharmaceuticals outside of Scandinavia. Although Newbury's focus is on the Scandinavian markets, export opportunities arise which contribute to improved sales and profitability.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Export order received](#)